Clinical trials
Fallopian Tube Carcinoma clinical trials
Below are recruiting fallopian tube carcinoma clinical trials, each written for real people, not researchers. We’re tracking 81 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06824467RecruitingPhase 3
Maintenance Therapy Study for Recurrent Ovarian Cancer
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
Birmingham, AlabamaAges 18 years+ - NCT06690775RecruitingPhase 2
Study of a new drug for platinum-resistant ovarian cancer
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
Phoenix, ArizonaAges 18 years+ - NCT06617923RecruitingPhase 2
Senaparib and Temozolomide for ARID1A-Mutated Ovarian Cancer
This trial tests a combination of two drugs, senaparib and temozolomide, for women with a specific type of ovarian cancer that has come back or is resistant to platinum-based chemotherapy. It is for patients whose tumor has a change in the ARID1A gene.
Baltimore, MarylandAges 18 years+ - NCT05009082RecruitingPhase 3
Niraparib alone or with bevacizumab for advanced ovarian cancer
This trial studies whether niraparib works better when combined with bevacizumab after chemotherapy and surgery for advanced ovarian, fallopian tube, or peritoneal cancer. If you qualify, you may help researchers find a treatment plan that controls the cancer for longer.
AmbergAges 18 years+ - NCT06161025RecruitingPhase 2/Phase 3
Raludotatug Deruxtecan for resistant ovarian cancer
This study tests a new drug called Raludotatug Deruxtecan (R-DXd) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if R-DXd can shrink tumors or slow cancer growth.
Anchorage, AlaskaAges 18 years+ - NCT05887609RecruitingPhase 2
Maintenance treatment for FRalpha-positive ovarian or endometrial cancer
This Phase 2 trial tests a combination of two medicines (mirvetuximab soravtansine and olaparib) as ongoing “maintenance” treatment after your best response to prior platinum chemotherapy. It may help keep cancer from growing longer in certain women whose tumors strongly match a specific marker (FRalpha).
Irvine, CaliforniaAges 18–100 - NCT05071937RecruitingPhase 2
Talazoparib plus ZEN003694 for recurrent ovarian cancer
This Phase 2 trial tests whether combining ZEN003694 with talazoparib can slow or shrink recurrent ovarian, fallopian tube, or primary peritoneal cancer. It is designed for people who have already been treated with a PARP inhibitor before, and it may help if that cancer comes back.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04516447RecruitingPhase 1
Testing a new drug for advanced ovarian cancer
This Phase 1 trial studies how well and how safely azenosertib (ZN-c3) works in people with advanced ovarian, fallopian tube, or peritoneal cancer. It may help by offering a new treatment option for cancers that don’t respond well to platinum chemotherapy (platinum-resistant).
Aurora, ColoradoAges 18 years+ - NCT03564340RecruitingPhase 1/Phase 2
Testing ubamatamab alone or with cemiplimab for ovarian and MUC16+ cancers
This early-phase study tests ubamatamab, a cancer-targeting antibody, given by itself or with cemiplimab. It is meant to treat adults whose cancer has come back and who may not have other good standard options left.
Birmingham, AlabamaAges 18 years+
Hear when a new Fallopian Tube Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for fallopian tube carcinoma?
- Yes. Clin2 currently lists 81 recruiting fallopian tube carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a fallopian tube carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a fallopian tube carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.